Lost in translation? IL28B's discovery and the journey back to the patient
Paul J. Clark, Andrew J. Muir – 18 April 2012
Introduction to the genetics and biology of interleukin‐28B
Thomas Urban, Michael R. Charlton, David B. Goldstein – 18 April 2012
Contrast‐enhanced ultrasound diagnosis of splenic artery steal syndrome after orthotopic liver transplantation
Xian‐Sheng Zhu, Yun‐Hua Gao, Sha‐Sha Wang, Qi Cheng, Yin Ling, Li Fan, Feng Huo, Miao‐Shui Pu, Peng Li – 18 April 2012 – The aim of this study was to investigate the use of contrast‐enhanced ultrasound (CEUS) for the detection of splenic artery steal syndrome (SASS) after orthotopic liver transplantation (OLT). Two hundred forty‐seven patients underwent OLT. Blood tests and color Doppler flow imaging (CDFI) were performed at various time points after the operation. CEUS and celiac angiography were used for patients suspected of having SASS.
Subcutaneous hepatitis B immune globulin after liver transplantation
Eric M. Yoshida, Nilu Partovi, Erica D. Greanya – 18 April 2012
Small‐for‐size syndrome after living donor liver transplantation: Successful treatment with a transjugular intrahepatic portosystemic shunt
Li Xiao, Fuqiang Li, Bo Wei, Bo Li, Cheng Wei Tang – 18 April 2012 – Small‐for‐size syndrome (SFSS) is a serious complication after living donor liver transplantation (LDLT) that can disrupt liver regeneration and result in hepatic dysfunction. Until now, the treatment options for SFSS after LDLT have been very limited. Here we describe a patient with SFSS after LDLT who was successfully treated with a transjugular intrahepatic portosystemic shunt (TIPS).
Living donation for the very ill patient with type I hepatorenal syndrome: Are we ready?
Lewis Teperman – 18 April 2012
Clinical utility of interleukin‐28B testing in patients with genotype 1
Michelle Lai, Nezam H. Afdhal – 18 April 2012
Synergistic interaction of dietary cholesterol and dietary fat in inducing experimental steatohepatitis
Christopher Savard, Erica V. Tartaglione, Rahul Kuver, W. Geoffrey Haigh, Geoffrey C. Farrell, Savitha Subramanian, Alan Chait, Matthew M. Yeh, LeBris S. Quinn, George N. Ioannou – 16 April 2012 – The majority of patients with nonalcoholic fatty liver disease (NAFLD) have “simple steatosis,” which is defined by hepatic steatosis in the absence of substantial inflammation or fibrosis and is considered to be benign.
Is it safe to use a liver graft from a chagas disease–seropositive donor in a human immunodeficiency virus–positive recipient? A case report addressing a novel challenge in liver transplantation
Nicolás Goldaracena, Michelle Mayer Wolf, Emilio Quiñonez, Margarita Anders, Ricardo Mastai, Lucas McCormack – 16 April 2012 – This is the first report presenting a human immunodeficiency virus (HIV)–positive patient with fulminant hepatic failure receiving a liver graft from a Chagas disease–seropositive deceased donor.
Hepatic steatosis and steatohepatitis in human immunodeficiency virus/hepatitis C virus–coinfected patients
Juan Macías, Juan Berenguer, Miguel A. Japón, José A. Girón‐González, Antonio Rivero, Luis F. López‐Cortés, Ana Moreno, Manuel Márquez, José A. Iribarren, Enrique Ortega, Pilar Miralles, Nicolás Merchante, Juan A. Pineda – 16 April 2012 – Hepatic steatosis (HS) is frequent in human immunodeficiency virus (HIV)‐ and hepatitis C virus (HCV)‐coinfected patients. Antiretroviral therapy (ART) and metabolic alterations could induce HS. However, a protective effect of ART has been reported in a paired biopsy study.